Cardiol Therapeutics Inc. (CRDL)
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Drug Manufacturers - Specialty & Generic
Cardiol Therapeutics Inc.
| Form | Description | Links | |
|---|---|---|---|
| 6-K | |||
| 6-K | |||
| 6-K | |||
| SUPPL | |||
| 13G/A | |||
| 6-K | |||
| SUPPL | |||
| F-10/A | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| F-X | |||
| F-10 | |||
| 6-K | |||
| 13G/A | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 6-K | |||
| 13G/A | |||
| 6-K |
1-25 of 189 filings
Recent SEC filings with analysis
- 6-KCardiol Therapeutics filed unaudited Q3 2026 financials showing a quarterly net loss of CAD 13.3 million, widened from CAD 10.0 million a year earlier, with…
- 6-KCardiol Therapeutics has entered into an at-the-market equity offering agreement with Jefferies LLC, giving it the ability to issue and sell common shares for…
- 6-KCardiol Therapeutics (NASDAQ: CRDL) has entered into an at-the-market equity offering agreement with Jefferies LLC allowing it to sell up to US$75 million of…
- 6-KCardiol Therapeutics enrolled 110 patients in its Phase III MAVERIC trial of CardiolRx™ for recurrent pericarditis, hitting its original target ahead of…
- 6-KCardiol Therapeutics announced on September 16, 2026 that it has received over USD $7 million in proceeds from the exercise of outstanding common share…
- 6-KCardiol Therapeutics Inc.
- 6-KCardiol Therapeutics filed a 6-K containing its Development Agreement with Clinical Academic Research Organization, S.A.